TREACE MEDICAL CONCEPTS, INC.·4

Jan 23, 9:30 PM ET

Hair Mark 4

Research Summary

AI-generated summary

Updated

Treace Medical (TMCI) CFO Mark Hair Receives RSU Award

What Happened
Mark Hair, Chief Financial Officer of Treace Medical Concepts, Inc. (TMCI), received a grant of 375,000 restricted stock units (RSUs) on January 22, 2026 (Transaction code A). On the same date, 17,037 shares were surrendered/withheld to satisfy tax withholding obligations (Transaction code F). The grant and withholding were reported at $0.00 per share; the RSUs convert to one share of common stock upon vesting.

Key Details

  • Transaction dates: January 22, 2026 (reported on Form 4 filed Jan 23, 2026). Filing appears timely.
  • Grant: 375,000 RSUs (code A) — reported acquisition at $0.00.
  • Tax withholding: 17,037 shares surrendered (code F) at $0.00 to cover tax liabilities. Net new RSUs after withholding: 357,963.
  • Shares/RSUs referenced in footnotes: filing notes 351,134 RSUs previously included (F1) and a total of 726,134 RSUs referenced (F3), consistent with 351,134 existing RSUs + 375,000 new RSUs = 726,134.
  • Vesting: The RSUs vest in equal annual installments over 4 years, with first vesting on Jan 22, 2027 and final vesting on Jan 22, 2030, subject to continued service (Footnote F2).
  • Transaction codes explained: A = award/grant; F = payment of exercise price or tax liability (withheld shares).

Context
This was a grant of RSUs rather than an open-market purchase or sale. RSU grants are common compensation for executives and do not necessarily signal a near-term market view; the withheld shares for taxes are routine. The RSUs will only become shares if and when they vest over the next four years, subject to Hair’s continued service.